Clinical Trial Update: Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating whether larotrectinib can enhance radioiodine uptake in differentiated thyroid cancer, including pediatric patients, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Larotrectinib (larotrectinib)

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Differentiated Thyroid Cancer, Pediatric Cancer | Phase 2 | Status: RECRUITING